PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
43.21
+0.30 (+0.70%)
At close: 4:04PM EST
Stock chart is not supported by your current browser
Previous Close42.91
Open42.70
Bid0.00 x 1300
Ask0.00 x 1400
Day's Range42.35 - 43.38
52 Week Range33.20 - 45.81
Volume24,607,466
Avg. Volume21,741,607
Market Cap249.774B
Beta (3Y Monthly)0.73
PE Ratio (TTM)10.91
EPS (TTM)3.96
Earnings DateJan 28, 2019 - Feb 1, 2019
Forward Dividend & Yield1.36 (3.07%)
Ex-Dividend Date2018-11-08
1y Target Est43.79
Trade prices are not sourced from all markets
  • MARKETS: Stocks could bounce here, but I'm selling the rally
    Yahoo Finance Video16 hours ago

    MARKETS: Stocks could bounce here, but I'm selling the rally

    Risk markets continue to deliver mixed messages to traders and market participants. The latest price action suggests more downside -- but first -- with a possible bounce to the 2750 level in the S&P 500, says Yahoo Finance's Jared Blikre, who breaks it down with Jen Rogers and Myles Udland.

  • Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes
    Zacks16 hours ago

    Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes

    Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.

  • Why Pfizer Is Up 19% in 2018 So Far
    Motley Fool17 hours ago

    Why Pfizer Is Up 19% in 2018 So Far

    Here's what has investors revved up about the big pharma stock.

  • 3 Dividend Stocks Ideal for Retirees
    Motley Foolyesterday

    3 Dividend Stocks Ideal for Retirees

    If you're looking for a solid income stream to complement Social Security and saving, check out these three great dividend stocks.

  • Here's Why Sangamo Therapeutics Lost 12% Today
    Motley Foolyesterday

    Here's Why Sangamo Therapeutics Lost 12% Today

    Wall Street is growing increasingly concerned about the progress the company's making with a gene therapy for hemophilia A.

  • Reutersyesterday

    Pfizer loses drug patent fight in UK top court, may face claims

    Pfizer (PFE.N) lost the final round in a lengthy patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica, exposing the company to possible financial claims. The Supreme Court decision is a blow for the U.S. drugmaker -- which had sought to affirm a secondary medical use patent for the product -- and a win for generic drug companies Actavis, now renamed Allergan (AGN.N), and Mylan (MYL.O). Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.

  • Pfizer loses drug patent fight in UK top court, may face claims
    Reutersyesterday

    Pfizer loses drug patent fight in UK top court, may face claims

    Pfizer lost the final round in a lengthy patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica, exposing the company to possible financial claims. The Supreme Court decision is a blow for the U.S. drugmaker -- which had sought to affirm a secondary medical use patent for the product -- and a win for generic drug companies Actavis, now renamed Allergan, and Mylan. Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.

  • 7 Highest-Yielding Dow Dividend Stocks
    Kiplingeryesterday

    7 Highest-Yielding Dow Dividend Stocks

    Volatile markets like today's are a good time to remind long-term investors of the virtues of big, stable dividend stocks like those found in the Dow Jones Industrial Average. It's hard to beat blue-chip dividend stocks when it comes to long-term performance. Witness the highest-yielding Dow dividend stocks. Although not every name is necessarily a buy at current levels, each and every one has distinguished itself over the decades. Note that many of the highest-yielding Dow dividend payers rank among the best equity investments of all time. In several instances, these stocks remain top picks among Wall Street analysts, mutual fund managers and hedge fund managers today. Big, healthy balance sheets and reliable and rising dividends also tend to make the highest-yielding dividend stocks in the Dow Jones less volatile than the broader market. That can help income investors sleep better at night. Here are the highest-yielding Dow dividend stocks, with yields ranging from just more than 3% to over 5%. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond

  • Reuters3 days ago

    Walmart, Home Depot adopt health insurer tactic in drug copay battle

    Walmart and Home Depot , two of the top 10 U.S. employers, have embraced a health insurance strategy that punishes drugmakers for using discount cards to keep patients from switching or stopping their medications. Large U.S. companies have started tightly managing how employees and their family members use these popular discount, or copay, cards for everything from multiple sclerosis treatments to widely-used rheumatoid arthritis medications sold through a specialty pharmacy.

  • Pfizer (PFE) Stock Moves -0.38%: What You Should Know
    Zacks3 days ago

    Pfizer (PFE) Stock Moves -0.38%: What You Should Know

    In the latest trading session, Pfizer (PFE) closed at $44.11, marking a -0.38% move from the previous day.

  • These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
    Investor's Business Daily3 days ago

    These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece

    Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.

  • Corbus Pharmaceuticals Holdings’ Performance in 2018
    Market Realist4 days ago

    Corbus Pharmaceuticals Holdings’ Performance in 2018

    Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company focused on developing and commercializing products for rare, life-threatening inflammatory fibrotic diseases.

  • How Nektar Performed in the Third Quarter
    Market Realist4 days ago

    How Nektar Performed in the Third Quarter

    Nektar Therapeutics (NKTR) released its third-quarter results on November 8. On November 6, Nektar announced a clinical oncology collaboration with Pfizer (PFE) to evaluate the combination of NKTR-214 with avelumab and talazoparib in different cancer areas. Nektar Therapeutics generated total revenues of $27.76 million in the third quarter of 2018 as compared with $152.93 million in the comparable period of 2017.

  • Hedge Funds Continue to Sell Off Pfizer Inc. (PFE)
    Insider Monkey5 days ago

    Hedge Funds Continue to Sell Off Pfizer Inc. (PFE)

    The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]